India's 1st mRNA vaccine candidate gets DCGI nod for human trials
India's first indigenous mRNA vaccine candidate has received approval to initiate Phase 1 and 2 human clinical trials from Drugs Controller General of India (DCGI). Pune-based Gennova Biopharmaceuticals developed the COVID-19 vaccine candidate, HGCO19, in collaboration with US-based HDT Bio. The vaccine demonstrated "safety and immunogenicity" in rodent and non-human primate models, Gennova said.